JPMorgan Bets on Protara Therapeutics: Overweight Rating and $27 Target on Picibanil Replica

JPMorgan starts coverage on Protara Therapeutics with Overweight rating and $27 PT. TARA-002, a de-risked Picibanil replica, targets NMIBC bladder cancer and lymphatic malformations with strong clinical backing from Japan/Taiwan.